PHASE II SAFETY AND EFFICACY STUDY OF CG0070 ONCOLYTIC VECTOR REGIMEN IN PATIENTS WITH HIGH GRADE NON-MUSCLE INVASIVE BLADDER CARCINOMA DISEASE (NMIBC) WHO HAVE FAILED BCG AND REFUSED CYSTECTOMY
Status: Withdrawn prior to enrolment
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 07 Feb 2019
Price : $35 *
At a glance
- Drugs CG 0070 (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms exBOND
- Sponsors Cold Genesys
- 30 Jan 2019 Status changed from completed to withdrawn prior to enrolment.
- 31 Aug 2018 Biomarkers information updated
- 27 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.